Axogen Inc (AXGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Axogen Inc (AXGN) has a cash flow conversion efficiency ratio of 0.006x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.56 Million) by net assets ($244.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Axogen Inc fund operations to measure how many days the company can operate on defensive assets alone.
Axogen Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Axogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Axogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyfrowy Polsat SA
WAR:CPS
|
0.052x |
|
Margun Enerji Uretim Sanayi ve Ticaret AS
IS:MAGEN
|
-0.037x |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
-0.001x |
|
Hillenbrand Inc
NYSE:HI
|
-0.019x |
|
Shanghai Kingstar Winning Software
SHE:300253
|
-0.012x |
|
Shanxi Zhangze Electric Power Co Ltd
SHE:000767
|
0.120x |
|
Affle (India) Limited
NSE:AFFLE
|
0.056x |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
N/A |
Annual Cash Flow Conversion Efficiency for Axogen Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Axogen Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see Axogen Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $128.85 Million | $812.00K | 0.006x | -85.56% |
| 2024-12-31 | $103.91 Million | $4.54 Million | 0.044x | +173.05% |
| 2023-12-31 | $95.67 Million | $-5.72 Million | -0.060x | +62.44% |
| 2022-12-31 | $101.00 Million | $-16.07 Million | -0.159x | -33.56% |
| 2021-12-31 | $112.55 Million | $-13.40 Million | -0.119x | -52.37% |
| 2020-12-31 | $123.15 Million | $-9.63 Million | -0.078x | +48.02% |
| 2019-12-31 | $132.15 Million | $-19.87 Million | -0.150x | -23.74% |
| 2018-12-31 | $146.98 Million | $-17.86 Million | -0.122x | +66.87% |
| 2017-12-31 | $25.18 Million | $-9.24 Million | -0.367x | +51.15% |
| 2016-12-31 | $14.92 Million | $-11.20 Million | -0.751x | +52.85% |
| 2015-12-31 | $8.20 Million | $-13.05 Million | -1.593x | -271.36% |
| 2014-12-31 | $-11.25 Million | $-10.45 Million | 0.929x | +101.22% |
| 2013-12-31 | $136.63K | $-10.44 Million | -76.444x | -2597.08% |
| 2012-12-31 | $-2.83 Million | $-8.66 Million | 3.061x | +362.55% |
| 2011-12-31 | $6.07 Million | $-7.08 Million | -1.166x | -381.30% |
| 2010-12-31 | $10.03 Million | $-2.43 Million | -0.242x | -117.35% |
| 2009-12-31 | $11.06 Million | $15.44 Million | 1.396x | +192.99% |
| 2008-12-31 | $313.19K | $-470.16K | -1.501x | -188.97% |
| 2007-12-31 | $898.82K | $-466.95K | -0.520x | -2239.79% |
| 2006-12-31 | $1.30 Million | $-28.79K | -0.022x | +94.79% |
| 2005-12-31 | $1.66 Million | $-709.62K | -0.426x | -210.74% |
| 2004-12-31 | $2.28 Million | $878.84K | 0.385x | +116.91% |
| 2003-12-31 | $-153.77K | $-27.30K | 0.178x | +122.73% |
| 2002-12-31 | $966.80K | $-755.02K | -0.781x | +5.42% |
| 2001-12-31 | $3.54 Million | $-2.92 Million | -0.826x | -206.41% |
| 2000-12-31 | $4.72 Million | $-1.27 Million | -0.269x | -721.89% |
| 1999-12-31 | $6.10 Million | $-200.00K | -0.033x | -118.36% |
| 1998-12-31 | $8.40 Million | $1.50 Million | 0.179x | +1471.43% |
| 1997-12-31 | $8.80 Million | $100.00K | 0.011x | -38.07% |
| 1996-12-31 | $10.90 Million | $200.00K | 0.018x | +105.50% |
| 1995-12-31 | $11.20 Million | $100.00K | 0.009x | 0.00% |
| 1994-12-31 | $11.20 Million | $100.00K | 0.009x | -67.26% |
| 1993-12-31 | $11.00 Million | $300.00K | 0.027x | -79.94% |
| 1992-12-31 | $10.30 Million | $1.40 Million | 0.136x | +19.86% |
| 1991-12-31 | $9.70 Million | $1.10 Million | 0.113x | -23.24% |
| 1990-12-31 | $8.80 Million | $1.30 Million | 0.148x | +69.89% |
| 1989-12-31 | $6.90 Million | $600.00K | 0.087x | -- |
About Axogen Inc
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed periphera… Read more